Advertisement

International Journal of Hematology

, Volume 107, Issue 1, pp 117–121 | Cite as

Pseudo-autologous stem cell transplantation for donor-derived mantle cell lymphoma 12 years after allogeneic transplantation

  • Masaharu Tamaki
  • Hidenori Wada
  • Ayumi Gomyo
  • Jin Hayakawa
  • Yu Akahoshi
  • Naonori Harada
  • Machiko Kusuda
  • Yuko Ishihara
  • Koji Kawamura
  • Aki Tanihara
  • Miki Sato
  • Kiriko Terasako-Saito
  • Kazuaki Kameda
  • Misato Kikuchi
  • Shun-ichi Kimura
  • Hideki Nakasone
  • Shinichi Kako
  • Yoshinobu Kanda
Case Report

Abstract

Donor-derived malignancy is a rare morbidity after allogeneic hematopoietic stem cell transplantation (HSCT), in which most previous cases have presented as acute leukemia or myelodysplastic syndrome. There have, however, been very few reports of donor-derived lymphoma. Here, we present a case of donor-derived mantle cell lymphoma 12 years after allogeneic HSCT, which was successfully treated with chemotherapy followed by pseudo-autologous HSCT (pASCT), i.e., an autologous HSC transplant following allogeneic HSCT in which the infused stem cell is considered to be derived from the donor cells. Although pASCT carries the risk of graft-versus-host disease (GVHD) due to the reinfusion of donor-derived peripheral blood cells, the present case did not develop GVHD without prophylaxis. The current case and a small number of previous reports suggest that the duration between allogeneic HSCT and pASCT may be important to the induction of immune tolerance, but further study in a larger number of cases is needed.

Keywords

Donor-derived malignancy Pseudo-autologous transplantation Mantle cell lymphoma 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Fialkow PJ, Thomas ED, Bryant JI, Neiman PE. Leukaemic transformation of engrafted human marrow cells in vivo. Lancet (London, England). 1971;1(7693):251–5.CrossRefGoogle Scholar
  2. 2.
    Kato M, Yamashita T, Suzuki R, Matsumoto K, Nishimori H, Takahashi S, et al. Donor cell-derived hematological malignancy: a survey by the Japan society for hematopoietic cell transplantation. Leukemia. 2016;30(8):1742–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Cooley LD, Sears DA, Udden MM, Harrison WR, Baker KR. Donor cell leukemia: report of a case occurring 11 years after allogeneic bone marrow transplantation and review of the literature. Am J Hematol. 2000;63(1):46–53.CrossRefPubMedGoogle Scholar
  4. 4.
    Sala-Torra O, Hanna C, Loken MR, Flowers ME, Maris M, Ladne PA, et al. Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(5):511–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Pusic I, Pavletic SZ, Kessinger A, Tarantolo SR, Bishop MR. Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease. Bone Marrow Transplant. 2002;29(8):709–10.CrossRefPubMedGoogle Scholar
  6. 6.
    Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, et al. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. 2016;172(1):80–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Czuczman MS, Goy A, Lamonica D, Graf DA, Munteanu MC, van der Jagt RH. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Ann Hematol. 2015;94(12):2025–32.CrossRefPubMedGoogle Scholar
  8. 8.
    Sugimoto M, Ito S, Mashima K, Umino K, Minakata D, Nakano H, et al. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. Ann Hematol. 2016;95(9):1513–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Christian B, Zhao W, Hamadani M, Sotomayor EM, Navarro W, Devine SM, et al. Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor. J Clin Oncol. 2010;28(31):e629–32.CrossRefPubMedGoogle Scholar
  10. 10.
    Atilla E, Atilla PA, Demirer T. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now? Int J Hematol. 2017;105(3):257–64.CrossRefPubMedGoogle Scholar
  11. 11.
    Palfreyman E, Song K, Nantel S. Pseudo-autologous hematopoietic SCT as treatment for a patient with multiple myeloma who relapsed following an allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48(8):1138.CrossRefPubMedGoogle Scholar
  12. 12.
    Hatsuse M, Taniguchi-Yoshihara K, Yagyu S, Fuchida S, Okano A, Murakami S, et al. Successful treatment with pseudo-autologous blood stem cell transplantation for an adolescent-onset multiple myeloma who relapsed after allogenic bone marrow transplantation. Rinsho ketsueki. 2015;56(4):428–31.PubMedGoogle Scholar
  13. 13.
    Jaing TH, Tseng CK, Mun-Ching Wong A, Lo WC, Wu CT, Ou LS. Rescue by hematopoietic progenitor cells derived from engrafted cord blood unit in a child with brain tumor after transplantation for T-cell acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2012;34(7):573–5.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  • Masaharu Tamaki
    • 1
  • Hidenori Wada
    • 1
  • Ayumi Gomyo
    • 1
  • Jin Hayakawa
    • 1
  • Yu Akahoshi
    • 1
  • Naonori Harada
    • 1
  • Machiko Kusuda
    • 1
  • Yuko Ishihara
    • 1
  • Koji Kawamura
    • 1
  • Aki Tanihara
    • 1
  • Miki Sato
    • 1
  • Kiriko Terasako-Saito
    • 1
  • Kazuaki Kameda
    • 1
  • Misato Kikuchi
    • 1
  • Shun-ichi Kimura
    • 1
  • Hideki Nakasone
    • 1
  • Shinichi Kako
    • 1
  • Yoshinobu Kanda
    • 1
  1. 1.Division of Hematology, Saitama Medical CenterJichi Medical UniversitySaitamaJapan

Personalised recommendations